|
1) Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008; 51: 415-26
|
|
|
|
2) Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4: 977-87
|
|
|
|
|
|
3) Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005; 97: 1232-5
|
|
|
|
|
|
4) Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des. 2007; 13: 1771-86
|
|
|
|
|
|
5) Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001; 108: 391-7
|
|
|
|
|
|
6) Casani L, Sanchez-Gomez S, Vilahur G, et al. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost. 2005; 94: 1035-41
|
|
|
|
|
|
7) Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003; 107: 2493-8
|
|
|
|
|
|
8) Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999; 100: 2131-4
|
|
|
|
|
|
9) Horiuchi M, Cui TX, Li Z, et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003; 107: 106-12
|
|
|
|
|
|
10) Ito M, Adachi T, Pimentel DR, et al. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation. 2004; 110: 412-8
|
|
|
|
|
|
11) Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol. 2007; 50: 359-67
|
|
|
|
|
|
12) Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007; 50: 2021-8
|
|
|
|
|
|
13) Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356: 930-3
|
|
|
|
|
|
14) Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007; 49: 2231-7
|
|
|
|
|
|
15) Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004; 363: 892-4
|
|
|
|
|
|
16) Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004; 93: 1124-9
|
|
|
|
|
|
17) Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43: 642-8
|
|
|
|
|
|
18) Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005; 165: 62-7
|
|
|
|
|
|
19) Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006; 113: 1086-92
|
|
|
|
|
|
20) Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006; 296: 2105-11
|
|
|
|
|
|
21) Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007; 115: 576-83
|
|
|
|
|
|
22) Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47: 332-7
|
|
|
|
|
|
23) Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003; 108: 839-43
|
|
|
|
|
|
24) Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005; 179: 201-6
|
|
|
|
|
|
25) Hong YJ, Jeong MH, Hyun DW, et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005; 95: 619-22
|
|
|
|
|
|
26) Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005; 111: 2356-63
|
|
|
|
|
|
27) Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007; 13: 1-7
|
|
|
|
|
|
28) Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008; 14: 140-4
|
|
|
|
|
|
29) Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-61
|
|
|
|
|
|
30) Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004; 6: 635-41
|
|
|
|
|